Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
149 participants
INTERVENTIONAL
2011-09-30
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis
NCT06899399
Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
NCT01163604
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects
NCT01349114
Revacept in Symptomatic Carotid Stenosis
NCT01645306
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
NCT01165983
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis
stent
patients receiving renal artery stenting for renal artery atherosclerosis
Aspirine
100mg Qd
Clopidogrel
75mg Qd
Lercanidipine
10-20mg Qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
stent
patients receiving renal artery stenting for renal artery atherosclerosis
Aspirine
100mg Qd
Clopidogrel
75mg Qd
Lercanidipine
10-20mg Qd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diameter of stenosis of renal artery or main branch of renal artery ≥60％. If diameter of stenosis is 60% - 75%, pressure difference between proximal and distal end ≥20 mm Hg (1mmHg=0.133kPa) or Captopril renography positive;
* Systolic blood pressure before taking antihypertensive ≥180mmHg and/or diastolic blood pressure ≥110 mmHg; taking three antihypertensive including one diuretics with systolic blood pressure ≥140mmHg and/or ≥90 mmHg;
* length of ipsilateral kidney is greater than 7.0cm.
Exclusion Criteria
* unstable condition and unable to tolerate interventional therapy;
* anatomy of renal artery pathology not suitable for interventional therapy;
* allergic to dihydropyridines;
* III degree atrioventricular block
* contrast allergy ;
* any known malignant tumor;
* non-compliant, history of alcoholism or drug abuse.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lee's Pharmaceutical Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuwai Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Zhaoke-1503-zanidip
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.